Brief: vTv Therapeutics Announces FDA Submission For First Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes
04/03/2024 15:06
March 4 (Reuters) - vTv Therapeutics Inc VTVT.O :
* VTV THERAPEUTICS ANNOUNCES FDA SUBMISSION FOR FIRST PHASE
3
STUDY OF CADISEGLIATIN IN PATIENTS WITH TYPE 1 DIABETES
Source text for Eikon: ID:nGNX5XkZhz
Further company coverage: VTVT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)